32 results on '"Yamamura, Soichiro"'
Search Results
2. Interaction and cross-talk between non-coding RNAs.
- Author
-
Yamamura, Soichiro, Imai-Sumida, Mitsuho, Tanaka, Yuichiro, and Dahiya, Rajvir
- Subjects
- *
NON-coding RNA , *GENE expression , *MICRORNA , *GENETIC regulation , *RNA - Abstract
Non-coding RNA (ncRNA) has been shown to regulate diverse cellular processes and functions through controlling gene expression. Long non-coding RNAs (lncRNAs) act as a competing endogenous RNAs (ceRNAs) where microRNAs (miRNAs) and lncRNAs regulate each other through their biding sites. Interactions of miRNAs and lncRNAs have been reported to trigger decay of the targeted lncRNAs and have important roles in target gene regulation. These interactions form complicated and intertwined networks. Certain lncRNAs encode miRNAs and small nucleolar RNAs (snoRNAs), and may regulate expression of these small RNAs as precursors. SnoRNAs have also been reported to be precursors for PIWI-interacting RNAs (piRNAs) and thus may regulate the piRNAs as a precursor. These miRNAs and piRNAs target messenger RNAs (mRNAs) and regulate gene expression. In this review, we will present and discuss these interactions, cross-talk, and co-regulation of ncRNAs and gene regulation due to these interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Genistein Inhibits Prostate Cancer Cell Growth by Targeting miR-34a and Oncogenic HOTAIR.
- Author
-
Chiyomaru, Takeshi, Yamamura, Soichiro, Fukuhara, Shinichiro, Yoshino, Hirofumi, Kinoshita, Takashi, Majid, Shahana, Saini, Sharanjot, Chang, Inik, Tanaka, Yuichiro, Enokida, Hideki, Seki, Naohiko, Nakagawa, Masayuki, and Dahiya, Rajvir
- Subjects
- *
PROSTATE cancer , *GENISTEIN , *CANCER cell growth , *MICRORNA , *APOPTOSIS , *CELL proliferation , *TUMOR suppressor proteins , *CELLULAR signal transduction - Abstract
Objective: Genistein is a soy isoflavone that has antitumor activity both in vitro and in vivo. It has been shown that genistein inhibits many type of cancers including prostate cancer (PCa) by regulating several cell signaling pathways and microRNAs (miRNAs). Recent studies suggest that the long non-coding RNAs (lncRNAs) are also involved in many cellular processes. At present there are no reports about the relationship between gensitein, miRNAs and lncRNAs. In this study, we focused on miRNAs, lncRNA that are regulated by genistein and investigated their functional role in PCa. Method: Microarray (SurePrint G3 Human GE 8×60K) was used for expression profiling of genistein treated and control PCa cells (PC3 and DU145). Functional assay (cell proliferation, migration, invasion, apoptosis and cell cycle assays) were performed with the PCa cell lines, PC3 and DU145. Both in vitro and in vivo (nude mouse) models were used for growth assays. Luciferase reporter assays were used for binding of miR-34a to HOTAIR. Results: LncRNA profiling showed that HOTAIR was highly regulated by genistein and its expression was higher in castration-resistant PCa cell lines than in normal prostate cells. Knockdown (siRNA) of HOTAIR decreased PCa cell proliferation, migration and invasion and induced apoptosis and cell cycle arrest. miR-34a was also up-regulated by genistein and may directly target HOTAIR in both PC3 and DU145 PCa cells. Conclusions: Our results indicated that genistein inhibited PCa cell growth through down-regulation of oncogenic HOTAIR that is also targeted by tumor suppressor miR-34a. These findings enhance understanding of how genistein regulates lncRNA HOTAIR and miR-34a in PCa. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Genistein Up-Regulates Tumor Suppressor MicroRNA-574-3p in Prostate Cancer.
- Author
-
Chiyomaru, Takeshi, Yamamura, Soichiro, Fukuhara, Shinichiro, Hidaka, Hideo, Majid, Shahana, Saini, Sharanjot, Arora, Sumit, Deng, Guoren, Shahryari, Varahram, Chang, Inik, Tanaka, Yuichiro, Tabatabai, Z. Laura, Enokida, Hideki, Seki, Naohiko, Nakagawa, Masayuki, and Dahiya, Rajvir
- Subjects
- *
PROSTATE cancer treatment , *TUMOR suppressor genes , *GENISTEIN , *MICRORNA , *GENE expression , *POLYMERASE chain reaction , *CANCER invasiveness , *CANCER cells , *CELLULAR signal transduction - Abstract
Genistein has been shown to inhibit cancers both in vitro and in vivo, by altering the expression of several microRNAs (miRNAs). In this study, we focused on tumor suppressor miRNAs regulated by genistein and investigated their function in prostate cancer (PCa) and target pathways. Using miRNA microarray analysis and real-time RT-PCR we observed that miR-574-3p was significantly up-regulated in PCa cells treated with genistein compared with vehicle control. The expression of miR-574-3p was significantly lower in PCa cell lines and clinical PCa tissues compared with normal prostate cells (RWPE-1) and adjacent normal tissues. Low expression level of miR-574-3p was correlated with advanced tumor stage and higher Gleason score in PCa specimens. Re-expression of miR-574-3p in PCa cells significantly inhibited cell proliferation, migration and invasion in vitro and in vivo. miR-574-3p restoration induced apoptosis through reducing Bcl-xL and activating caspase-9 and caspase-3. Using GeneCodis software analysis, several pathways affected by miR-574-3p were identified, such as ‘Pathways in cancer’, ‘Jak-STAT signaling pathway’, and ‘Wnt signaling pathway’. Luciferase reporter assays demonstrated that miR-574-3p directly binds to the 3′ UTR of several target genes (such as RAC1, EGFR and EP300) that are components of ‘Pathways in cancer’. Quantitative real-time PCR and Western analysis showed that the mRNA and protein expression levels of the three target genes in PCa cells were markedly down-regulated with miR-574-3p. Loss-of-function studies demonstrated that the three target genes significantly affect cell proliferation, migration and invasion in PCa cell lines. Our results show that genistein up-regulates tumor suppressor miR-574-3p expression targeting several cell signaling pathways. These findings enhance understanding of how genistein regulates with miRNA in PCa. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
5. Genistein Suppresses Prostate Cancer Growth through Inhibition of Oncogenic MicroRNA-151.
- Author
-
Chiyomaru, Takeshi, Yamamura, Soichiro, Zaman, Mohd Saif, Majid, Shahana, Deng, Guoren, Shahryari, Varahram, Saini, Sharanjot, Hirata, Hiroshi, Ueno, Koji, Chang, Inik, Tanaka, Yuichiro, Tabatabai, Z. Laura, Enokida, Hideki, Nakagawa, Masayuki, Dahiya, Rajvir, and Sarkar, Fazlul H.
- Subjects
- *
GENISTEIN , *CANCER , *MICRORNA , *PROSTATE cancer , *TUMORS , *ONCOGENIC viruses - Abstract
Genistein has been shown to suppress the growth of several cancers through modulation of various pathways. However, the effects of genistein on the regulation of oncogenic microRNA-151 (miR-151) have not been reported. In this study, we investigated whether genistein could alter the expression of oncogenic miR-151 and its target genes that are involved in the progression and metastasis of prostate cancer (PCa). Real-time RT-PCR showed that the expression of miR-151 was higher in PC3 and DU145 cells compared with RWPE-1 cells. Treatment of PC3 and DU145 cells with 25 µM genistein down-regulated the expression of miR- 151 compared with vehicle control. Inhibition of miR-151 in PCa cells by genistein significantly inhibited cell migration and invasion. In-silico analysis showed that several genes (CASZ1, IL1RAPL1, SOX17, N4BP1 and ARHGDIA) suggested to have tumor suppressive functions were target genes of miR-151. Luciferase reporter assays indicated that miR-151 directly binds to specific sites on the 39UTR of target genes. Quantitative real-time PCR analysis showed that the mRNA expression levels of the five target genes in PC3 and DU145 were markedly changed with miR-151 mimics and inhibitor. Kaplan-Meier curves and log- rank tests revealed that high expression levels of miR-151 had an adverse effect on survival rate. This study suggests that genistein mediated suppression of oncogenic miRNAs can be an important dietary therapeutic strategy for the treatment of PCa. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma.
- Author
-
Yamamura, Soichiro, Saini, Sharanjot, Majid, Shahana, Hirata, Hiroshi, Ueno, Koji, Chang, Inik, Tanaka, Yuichiro, Gupta, Ashish, and Dahiya, Rajvir
- Subjects
- *
MICRORNA , *GENE targeting , *MYC oncogenes , *GENETIC transcription , *RENAL cell carcinoma , *GENETIC regulation , *LUCIFERASES , *ONCOGENES , *GENETICS - Abstract
We investigated the functional effects of microRNA-34a (miR-34a) on c-Myc transcriptional complexes in renal cell carcinoma. miR-34a down-regulated expression of multiple oncogenes including c-Myc by targeting its 3′ untranslated region, which was revealed by luciferase reporter assays. miR-34a was also found to repress RhoA expression by suppressing the c-Myc–Skp2–Miz1 transcriptional complex that activates RhoA. Overexpression of c-Myc reversed miR-34a suppression of RhoA expression and inhibition of cell invasion, suggesting that miR-34a inhibits invasion by suppressing RhoA through c-Myc. miR-34a was also found to repress the c-Myc–P-TEFb transcription elongation complex, indicating one of the mechanisms by which miR-34a has profound effects on cellular functions. Our results demonstrate that miR-34a suppresses assembly and function of the c-Myc complex that activates or elongates transcription, indicating a novel role of miR-34a in the regulation of transcription by c-Myc. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
7. MicroRNA-34a Modulates c-Myc Transcriptional Complexes to Suppress Malignancy in Human Prostate Cancer Cells.
- Author
-
Yamamura, Soichiro, Saini, Sharanjot, Majid, Shahana, Hirata, Hiroshi, Ueno, Koji, Deng, Guoren, and Dahiya, Rajvir
- Subjects
- *
P53 protein , *CANCER cells , *TUMOR suppressor proteins , *PROSTATE cancer , *GENE transfection , *CELL proliferation - Abstract
MicroRNA-34a (miR-34a), a potent mediator of tumor suppressor p53, has been reported to function as a tumor suppressor and miR-34a was found to be downregulated in prostate cancer tissues. We studied the functional effects of miR-34a on c- Myc transcriptional complexes in PC-3 prostate cancer cells. Transfection of miR-34a into PC-3 cells strongly inhibited in vitro cell proliferation, cell invasion and promoted apoptosis. Transfection of miR-34a into PC-3 cells also significantly inhibited in vivo xenograft tumor growth in nude mice. miR-34a downregulated expression of c-Myc oncogene by targeting its 3' UTR as shown by luciferase reporter assays. miR-34a was found to repress RhoA, a regulator of cell migration and invasion, by suppressing c-Myc-Skp2-Miz1 transcriptional complex that activates RhoA. Overexpression of c-Myc reversed miR-34a suppression of RhoA expression, suggesting that miR-34a inhibits invasion by suppressing RhoA through c-Myc. miR-34a was also found to repress c-Myc-pTEFB transcription elongation complex, indicating one of the mechanisms by which miR- 34a has profound effects on cellular function. This is the first report to document that miR-34a suppresses assembly and function of the c-Myc-Skp2-Miz1 complex that activates RhoA and the c-Myc-pTEFB complex that elongates transcription of various genes, suggesting a novel role of miR-34a in the regulation of transcription by c-Myc complex. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
8. MicroRNA-708 Induces Apoptosis and Suppresses Tumorigenicity in Renal Cancer Cells.
- Author
-
Saini, Sharanjot, Yamamura, Soichiro, Majid, Shahana, Shahryari, Varahram, Hirata, Hiroshi, Tanaka, Yuichiro, and Dahiya, Rajvir
- Subjects
- *
APOPTOSIS , *CARCINOGENESIS , *CELL division , *CANCER cells , *RENAL cell carcinoma - Abstract
Cancer pathogenesis is restricted by stresses that compromise cell division and survival. In this study, we identify miR-708, a little studied member of a set of microRNAs that have been implicated in stress control, as an important tumor suppressor in renal cell carcinoma (RCC). miR-708 expression was attenuated widely in human RCC specimens. Restoration of miR-708 expression in RCC cell lines decreased cell growth, clonability, invasion, and migration and elicited a dramatic increase in apoptosis. Moreover, intratumoral delivery of miR-708 was sufficient to trigger in vivo regression of established tumors in murine xenograft models of human RCC. Investigation of the targets of miR-708 identified the inhibitor of apoptosis protein survivin as important. siRNA-mediated knockdown of survivin partially phenocopied miR-708 overexpression suggesting that the proapoptotic role of miR-708 may be mediated primarily through survivin regulation. Additionally, we identified the E-cadherin regulators ZEB2 and BMI1 as likely miR-708 targets. Taken together, our findings define a major tumor suppressive role for miR-708, which may offer an attractive new target for prognostic and therapeutic intervention in RCC. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
9. Sphingosine 1-Phosphate Breakdown in Platelets.
- Author
-
Yatomi, Yutaka, Yamamura, Soichiro, Hisano, Nobuo, Nakahara, Kazuhiko, Igarashi, Yasuyuki, and Ozaki, Yukio
- Subjects
- *
BLOOD platelets , *BIOGENIC amines , *ETHANOLAMINES , *SPHINGOSINE , *HEMOSTATICS , *SERINE proteinases - Abstract
We examined the formation of sphingolipid mediators in platelets, which abundantly store, and release extracellularly, sphingosine 1-phosphate (Sph-1-P). Challenging [3H]Sph-labeled platelet suspensions with thrombin or 12-O-tetradecanoylphorbol 13-acetate (TPA) resulted in a decrease in Sph-1-P formation and an increase in sphingosine (Sph), ceramide (Cer), and sphingomyelin formation. Sph conversion into Cer, and Cer conversion into sphingomyelin were not affected upon activation, suggesting that Sph-1-P dephosphorylation may initiate the formation of sphingolipid signaling molecules. In fact, Sph-1-P phosphatase (but not lyase) activity was detected in platelets, but this activity was not enhanced by thrombin or TPA. When quantified with [3H]acetic anhydride acetylation, followed by HPLC separation, the amounts of Sph-1-P and Sph decreased and increased, respectively, upon stimulation with thrombin or TPA, and these changes were attenuated by staurosporine. Under these TPA treatment conditions, over half of the [3H]Sph-1-P (formed in platelets incubated with [3H]Sph) was detected extracellularly, possibly due to its release from platelets, which was completely inhibited by staurosporine pretreatment. Furthermore, when TPA-induced Sph-1-P release was blocked by staurosporine after the stimulation, the extracellular [3H]Sph-1-P radioactivity decreased, suggesting that the Sph-1-P released may undergo dephosphorylation extracellularly. To support this, [32P]Sph-1-P, when added extracellularly to platelet suspensions, was rapidly degraded, possibly due to the ecto-phosphatase activity. Our results suggest the presence in anucleate platelets of a transmembrane cycling pathway starting with Sph-1-P dephosphorylation and leading to the formation of other sphingolipid mediators. [ABSTRACT FROM PUBLISHER]
- Published
- 2004
- Full Text
- View/download PDF
10. Coordination of p300-Mediated Chromatin Remodeling and TRAP/Mediator Function through Coactivator PGC-1α
- Author
-
Wallberg, Annika E., Yamamura, Soichiro, Malik, Sohail, Spiegelman, Bruce M., and Roeder, Robert G.
- Subjects
- *
TRANSCRIPTION factors , *PROTEINS , *CHROMATIN , *TRANSFERASES - Abstract
Transcriptional coactivators showing physical and functional interactions with PPARγ include the protein acetyl transferase p300, the TRAP/Mediator complex that interacts with the general transcription machinery, and the highly regulated PGC-1α. We show that PGC-1α directly interacts with TRAP/Mediator, through the PPARγ-interacting subunit TRAP220, and stimulates TRAP/Mediator-dependent function on DNA templates. Further, while ineffective by itself, PGC-1α stimulates p300-dependent histone acetylation and transcription on chromatin templates in response to PPARγ. These functions are mediated by largely independent PPARγ, p300, and TRAP220 interaction domains in PGC-1α, whereas p300 and TRAP220 show ligand-dependent interactions with a common region of PPARγ. Apart from showing PGC-1α functions both in chromatin remodeling and in preinitiation complex formation or function (transcription), these results suggest a key role for PGC-1α, through concerted but dynamic interactions, in coordinating these steps. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
11. Fluorescence measurement of glucose by pyrene-modified oxidase
- Author
-
Tatsu, Yoshiro and Yamamura, Soichiro
- Subjects
- *
GLUCOSE , *PYRENE , *OXIDASES , *FLUORESCENCE - Abstract
Glucose oxidase was chemically modified with pyrene. The fluorescence intensity of the modified oxidase increased by glucose. The increase was attributed to the enzymatic consumption of dissolved oxygen that quenched the fluorescence of pyrene. Glucose concentration was measured quantitatively from 1 to 17 mM by the fluorescence measurement. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
12. Sphingosine 1-phosphate regulates melanoma cell motility through a receptor-coupled extracellular...
- Author
-
Yamamura, Soichiro and Yatomi, Yutaka
- Subjects
- *
SPHINGOSINE , *BINDING sites , *BIOCHEMICAL mechanism of action - Abstract
Discusses the characteristics of specific cell-binding sites for sphingosine 1-phosphate (Sph-1-P) on surface of F10 cells. Purification of SPh-1-P binding proteins; Scatchard analysis of binding assay data; Relationship between cell motility inhibition and cell surface binding; Role of Sph-1-P.
- Published
- 1997
- Full Text
- View/download PDF
13. E Protein Silencing by the Leukemogenic AML1-ETO Fusion Protein.
- Author
-
Zhang, Jinsong, Kalkum, Markus, Yamamura, Soichiro, Chait, Brian T., and Roeder, Robert C.
- Subjects
- *
PROTEINS , *LEUCOCYTOSIS , *PRELEUKEMIA , *IMINO acids , *HAIRY cell leukemia , *HOMOLOGY (Biology) - Abstract
The AML1-ETO fusion protein, generated by the t(8;21) chromosomal translocation, is causally involved in nearly 15% of acute myeloid leukemia (AMI) cases. This study shows that AML1-ETO, as well as ETO, inhibits transcriptional activation by E proteins through stable interactions that preclude recruitment of p300/CREB-binding protein (CBP) coactivators. These interactions are mediated by a conserved ETO TAF4 homology domain and a 17-amino acid p300/CBP and ETO target motif within AD1 activation domains of E proteins. In t(8;21) leukemic cells, very stable interactions between AML1-ETO and E proteins underlie a t(8;21) translocation-specific silencing of E protein function through an aberrant cofactor exchange mechanism. These studies identify E proteins as AML1-ETO targets whose dysregulation may be important for t(8;21) leukemogenesis, as well as an E protein silencing mechanism that is distinct from that associated with differentiation-inhibitory proteins. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
14. Suppressor effect of catechol-O-methyltransferase gene in prostate cancer.
- Author
-
Hashimoto, Yutaka, Shiina, Marisa, Maekawa, Shigekatsu, Kato, Taku, Shahryari, Varahram, Kulkarni, Priyanka, Dasgupta, Pritha, Yamamura, Soichiro, Saini, Sharanjot, Tabatabai, Z. Laura, Dahiya, Rajvir, and Tanaka, Yuichiro
- Subjects
- *
PROSTATE cancer patients , *CATECHOL-O-methyltransferase , *CELL lines , *CANCER cells , *CELL proliferation , *BIOMARKERS , *MICRORNA , *POLYMERASE chain reaction - Abstract
Catechol-estrogens can cause genetic mutations and to counteract their oncogenicity, the catechol-O-methyltransferase (COMT) gene is capable of neutralizing these reactive compounds. In this study, we determined the functional effects and regulation of COMT in prostate cancer. Both the Cancer Genome Atlas (TCGA) and immunohistochemical analysis of clinical specimens demonstrated a reduction of COMT expression in prostate cancer. Also, western analyses of prostate cancer cell lines show COMT levels to be minimal in DuPro and DU145 and thus, these cells were used for further analyses. Re-expression of COMT led to suppressed migration ability (wound healing assay) and enhanced apoptosis (flow cytometric analyses), and when challenged with 4-hydroxyestradiol, a marked reduction of cell proliferation (MTT assay) was observed. Xenograft growth in athymic mice also resulted in inhibition due to COMT. As a mechanism, western analyses show cleaved CASP3 and BID were increased whereas XIAP and cIAP2 were reduced due to COMT. As COMT expression is low in prostate cancer, its regulation was determined. Databases identified several miRNAs capable of binding COMT and of these, miR-195 was observed to be increased in prostate cancer according to TCGA. Real-time PCR validated upregulation of miR-195 in clinical prostate cancer specimens as well as DuPro and DU145 and interestingly, luciferase reporter showed miR-195 capable of binding COMT and overexpressing miR-195 could reduce COMT in cells. These results demonstrate COMT to play a protective role by activating the apoptosis pathway and for miR-195 to regulate its expression. COMT may thus be a potential biomarker and gene of interest for therapeutic development for prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Role of miR-182/PDCD4 axis in aggressive behavior of prostate cancer in the African Americans.
- Author
-
Shiina, Marisa, Hashimoto, Yutaka, Kulkarni, Priyanka, Dasgupta, Pritha, Shahryari, Varahram, Yamamura, Soichiro, Tanaka, Yuichiro, and Dahiya, Rajvir
- Subjects
- *
PROSTATE cancer , *CANCER invasiveness , *AFRICAN Americans , *RACIAL inequality , *CELL lines - Abstract
Background: Prostate cancer is one of the most commonly diagnosed cancers among men. African Americans (AA) are at an increased risk of developing prostate cancer compared to European Americans (EA). miRNAs play a critical role in these tumors, leading to tumor progression. In this study, we investigated the role of miR-182 in racial disparity in prostate cancer.Results: We found significantly increased levels of miR-182 in prostate cancer tissues compared to BPH. Also, miR-182 shows increased expression in AA prostate cancer cell line and tissue samples compared to EA. We performed biochemical recurrence (BCR) - free survival time in AA and EA patients and found that high miR-182 expression had significantly shorter BCR-free survival than patients with low miR-182 expression (P = 0.031). To elucidate the role of miR-182, we knocked down miR-182 in EA (DU-145 and LNCaP) and AA (MDA-PCa-2b) cell lines and found an increase in apoptosis, arrest of the cell cycle, and inhibition of colony formation in the AA cell line to a greater extent than EA cell lines.Conclusions: Our results showed that PDCD4 is a direct miR-182 target and its inhibition is associated with aggressiveness and high Gleason grade in prostate cancer among AA. These findings show that miR-182 is highly expressed in AA patients and miR-182 may be a target for effective therapy in AA patients. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
16. Genistein Represses HOTAIR/Chromatin Remodeling Pathways to Suppress Kidney Cancer.
- Author
-
Imai-Sumida, Mitsuho, Dasgupta, Pritha, Kulkarni, Priyanka, Shiina, Marisa, Yutaka Hashimoto, Shahryari, Varahram, Majid, Shahana, Yuichiro Tanaka, Dahiya, Rajvir, and Yamamura, Soichiro
- Abstract
Background/Aims: Genistein, a soy isoflavone, has been shown to have anti-cancer effects in various cancers including renal cancer. Long non-coding RNA, HOX transcript antisense RNA (HOTAIR), is involved in cancer progression and metastasis, such as renal cancer. Our aim was to investigate the effects of genistein on HOTAIR chromatin remodeling functions. Methods: We used MTS assays and Transwell migration assays to study the effects of genistein on cell proliferation and migration respectively in human renal cell carcinoma (RCC) cell lines. We used Western blots to analyze SNAIL and ZO-1 expression. We performed chromatin immunoprecipitation (ChIP) assays to study recruitment of the polycomb repressive complex 2 (PRC2) to the ZO-1 promoter. We performed RNA immunoprecipitation (RIP) assays to study interaction between HOTAIR and PRC2, SMARCB1 or ARID1A. We also performed transfection experiments to overexpress EED, HOTAIR and knockdown SMARCB1. Results: Genistein reduced cell proliferation and migration of human renal cell carcinoma cell lines. ChIP assays indicated that genistein reduces recruitment of the PRC2 to the ZO-1 promoter and increased its expression. RIP assays showed that genistein inhibits HOTAIR interaction with PRC2, leading to tumor suppression. Immunoprecipitation also revealed that genistein reduced EED levels in PRC2, suggesting that decreased EED levels suppress HOTAIR interaction with PRC2. EED overexpression in the presence of genistein restored PRC2 interaction with HOTAIR and reduced ZO-1 transcription, suggesting genistein activates ZO-1 by inhibiting HOTAIR/PRC2 functions. RIP assays also showed that HOTAIR interacts with SMARCB1 and ARID1A, subunits of the human SWI/SNF chromatin remodeling complex and genistein reduces this interaction. Combination of HOTAIR overexpression and SMARCB1 knockdown in the presence of genistein revealed that genistein inhibits SNAIL transcription via the HOTAIR/SMARCB1 pathway. Conclusion: Genistein suppresses EED levels in PRC2 and inhibits HOTAIR/ PRC2 interaction. Genistein suppresses HOTAIR/PRC2 recruitment to the ZO-1 promoter and enhances ZO-1 transcription. Genistein also inhibits SNAIL transcription via reducing HOTAIR/SMARCB1 interaction. We demonstrate that the reduction of HOTAIR interaction with chromatin remodeling factors by genistein represses HOTAIR/chromatin remodeling pathways to suppress RCC malignancy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Correction: CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma.
- Author
-
Mitsui, Yozo, Chang, Inik, Fukuhara, Shinichiro, Hiraki, Miho, Arichi, Naoko, Yasumoto, Hiroaki, Hirata, Hiroshi, Yamamura, Soichiro, Shahryari, Varahram, Deng, Guoren, Wong, Darryn K., Majid, Shahana, Shiina, Hiroaki, Dahiya, Rajvir, and Tanaka, Yuichiro
- Published
- 2022
- Full Text
- View/download PDF
18. MicroRNA-4723 Inhibits Prostate Cancer Growth through Inactivation of the Abelson Family of Nonreceptor Protein Tyrosine Kinases.
- Author
-
Arora, Sumit, Saini, Sharanjot, Fukuhara, Shinichiro, Majid, Shahana, Shahryari, Varahram, Yamamura, Soichiro, Chiyomaru, Takeshi, Deng, Guoren, Tanaka, Yuichiro, and Dahiya, Rajvir
- Subjects
- *
MICRORNA , *PROSTATE cancer prevention , *TUMOR growth , *ABL1 gene , *PROTEIN-tyrosine kinases , *PROTO-oncogenes , *CELL proliferation - Abstract
The Abelson (c-Abl) proto-oncogene encodes a highly conserved nonreceptor protein tyrosine kinase that plays a role in cell proliferation, differentiation, apoptosis and cell adhesion. c-Abl represents a specific anti-cancer target in prostate cancer as aberrant activity of this kinase has been implicated in the stimulation of prostate cancer growth and progression. However, the mechanism of regulation of c-Abl is not known. Here we report that Abl kinases are regulated by a novel microRNA, miR-4723, in prostate cancer. Expression profiling of miR-4723 expression in a cohort of prostate cancer clinical specimens showed that miR-4723 expression is widely attenuated in prostate cancer. Low miR-4723 expression was significantly correlated with poor survival outcome and our analyses suggest that miR-4723 has significant potential as a disease biomarker for diagnosis and prognosis in prostate cancer. To evaluate the functional significance of decreased miR-4723 expression in prostate cancer, miR-4723 was overexpressed in prostate cancer cell lines followed by functional assays. miR-4723 overexpression led to significant decreases in cell growth, clonability, invasion and migration. Importantly, miR-4723 expression led to dramatic induction of apoptosis in prostate cancer cell lines suggesting that miR-4723 is a pro-apoptotic miRNA regulating prostate carcinogenesis. Analysis of putative miR-4723 targets showed that miR-4723 targets integrin alpha 3 and Methyl CpG binding protein in addition to Abl1 and Abl2 kinases. Further, we found that the expression of Abl kinase is inversely correlated with miR-4723 expression in prostate cancer clinical specimens. Also, Abl1 knockdown partially phenocopies miR-4723 reexpression in prostate cancer cells suggesting that Abl is a functionally relevant target of miR-4723 in prostate cancer. In conclusion, we have identified a novel microRNA that mediates regulation of Abl kinases in prostate cancer. This study suggests that miR-4723 may be an attractive target for therapeutic intervention in prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
19. MicroRNA-23b Functions as a Tumor Suppressor by Regulating Zeb1 in Bladder Cancer.
- Author
-
Majid, Shahana, Dar, Altaf A., Saini, Sharanjot, Deng, Guoren, Chang, Inik, Greene, Kirsten, Tanaka, Yuichiro, Dahiya, Rajvir, and Yamamura, Soichiro
- Subjects
- *
BLADDER cancer treatment , *MICRORNA , *TUMOR suppressor genes , *GENETIC code , *GENE expression , *NUCLEIC acids , *BIOMARKERS , *UROLOGY - Abstract
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression by targeted repression of transcription and translation. In this study we show that miRNA-23b (miR-23b) acts as a tumor suppressor in bladder cancer. Quantitative real-time PCR analysis showed that miR-23b is significantly down-regulated in bladder cancer cell lines and tumor tissues compared to non-malignant cells and normal tissue samples. We also demonstrate that miR-23b expression has a potential to be diagnostic and prognostic biomarker in bladder cancer. High miR-23b expression is positively correlated with higher overall survival of bladder cancer patients as revealed by Kaplan-Meier analysis. ROC analysis showed that miR-23b expression can distinguish between normal and bladder cancer tissues. Further we elucidated the biological significance of miR-23b in bladder cancer. Over-expression of miR-23b in bladder cancer cells inhibited cell proliferation and impaired colony formation. Fluorescence activated cell sorting (FACS) analysis revealed that re-expression of miR-23b in bladder cancer cells induced G0/G1 cell cycle arrest and apoptosis while inhibiting cell migration and invasion. Luciferase reporter assays demonstrated that Zeb1, a crucial regulator of epithelial-to-mesenchymal transition (EMT), is a direct target of miR-23b in bladder cancer. These results show that loss of miR-23b confers a proliferative advantage and promotes bladder cancer cell migration and invasion. Furthermore, re-expression of miR-23b may be a beneficial therapeutic strategy for the treatment of human bladder cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
20. miR-23b Represses Proto-oncogene Src Kinase and Functions as Methylation-Silenced Tumor Suppressor with Diagnostic and Prognostic Significance in Prostate Cancer.
- Author
-
Majid, Shahana, Dar, Altaf A., Saini, Sharanjot, Arora, Sumit, Shahryari, Varahram, Zaman, Mohd Saif, Inik Chang, Yamamura, Soichiro, Tanaka, Yuichiro, Guoren Deng, and Dahiya, Rajvir
- Subjects
- *
PROSTATE cancer treatment , *TUMOR suppressor genes , *BIOMARKERS , *TUMOR growth , *CANCER diagnosis , *CADHERINS - Abstract
The miRNAs have great potential as biomarkers and therapeutic agents owing to their ability to control multiple genes and potential to influence cellular behavior. Here, we identified that miR-23b is a methylation-silenced tumor suppressor in prostate cancer. We showed that miR-23b expression is controlled by promoter methylation and has great promise as a diagnostic and prognostic biomarker in prostate cancer. High levels of miR-23b expression are positively correlated with higher overall and recurrence-free survival in patients with prostate cancer. Furthermore, we elucidated the tumor suppressor role of miR-23b using in vitro and in vivo models. We showed that proto-oncogene Src kinase and Akt are direct targets of miR-23b. Increased expression of miR-23b inhibited proliferation, colony formation, migration/invasion, and triggered G0-G1 cell-cycle arrest and apoptosis in prostate cancer. Overexpression of miR-23b inhibited epithelial-to-mesenchymal transition (EMT) causing a decline in mesenchymal markers Vimentin and Snail and increasing the epithelial marker, E-cadherin. Depletion of Src by RNA interference conferred similar functional effects as that of miR-23b reconstitution. miR- 23b expression caused a dramatic decrease in tumor growth in nude mice and attenuated Src expression in excised tumors compared with a control miR. These findings suggest that miR-23b is a methylation-silenced tumor suppressor that may be a useful biomarker in prostate cancer. Loss of miR-23b may confer proliferative advantage and promote prostate cancer migration and invasion, and re-expression of miR-23b may contribute to the epigenetic therapy for prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
21. MicroRNA-1280 Inhibits Invasion and Metastasis by Targeting ROCK1 in Bladder Cancer.
- Author
-
Majid, Shahana, Dar, Altaf A., Saini, Sharanjot, Shahryari, Varahram, Arora, Sumit, Zaman, Mohd Saif, Chang, Inik, Yamamura, Soichiro, Chiyomaru, Takeshi, Fukuhara, Shinichiro, Tanaka, Yuichiro, Deng, Guoren, Tabatabai, Z. Laura, and Dahiya, Rajvir
- Subjects
- *
MICRORNA , *ONCOGENES , *TUMOR suppressor genes , *BLADDER cancer , *IN situ hybridization , *CELL lines , *CANCER - Abstract
MicroRNAs (miRNAs) are non-protein-coding sequences that can function as oncogenes or tumor suppressor genes. This study documents the tumor suppressor role of miR-1280 in bladder cancer. Quantitative real-time PCR and in situ hybridization analyses showed that miR-1280 is significantly down-regulated in bladder cancer cell lines and tumors compared to a non-malignant cell line or normal tissue samples. To decipher the functional significance of miR-1280 in bladder cancer, we ectopically over-expressed miR-1280 in bladder cancer cell lines. Over-expression of miR-1280 had antiproliferative effects and impaired colony formation of bladder cancer cell lines. FACS (fluorescence activated cell sorting) analysis revealed that re-expression of miR-1280 in bladder cancer cells induced G2-M cell cycle arrest and apoptosis. Our results demonstrate that miR-1280 inhibited migration and invasion of bladder cancer cell lines. miR-1280 also attenuated ROCK1 and RhoC protein expression. Luciferase reporter assays demonstrated that oncogene ROCK1 is a direct target of miR-1280 in bladder cancer. This study also indicates that miR-1280 may be of diagnostic and prognostic importance in bladder cancer. For instance, ROC analysis showed that miR-1280 expression can distinguish between malignant and normal bladder cancer cases and Kaplan-Meier analysis revealed that patients with miR-1280 high expression had higher overall survival compared to those with low miR-1280 expression. In conclusion, this is the first study to document that miR-1280 functions as a tumor suppressor by targeting oncogene ROCK1 to invasion/migration and metastasis. Various compounds are currently being used as ROCK1 inhibitors; therefore restoration of tumor suppressor miR-1280 might be therapeutically useful either alone or in combination with these compounds in the treatment of bladder cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
22. miRNA-708 Control of CD44+ Prostate Cancer--Initiating Cells.
- Author
-
Saini, Sharanjot, Majid, Shahana, Shahryari, Varahram, Arora, Sumit, Yamamura, Soichiro, Chang, Inik, Zaman, Mohd Saif, Deng, Guoren, Tanaka, Yuichiro, and Dahiya, Rajvir
- Subjects
- *
CD44 antigen , *PROSTATE cancer , *TUMORS , *XENOGRAFTS , *CANCER cells - Abstract
Tumor recurrence in prostate cancer has been attributed to the presence of CD44-expressing tumor-initiating cells. In this study, we report that miR-708 is a key negative regulator of this CD44+ subpopulation of prostate cancer cells, with important implications for diagnosis and prognosis of this disease. miR-708 was underexpressed in CD44+ cells from prostate cancer xenografts. Reconstitution of miR-708 in prostate cancer cell lines or CD44+ prostate cancer cells led to decreased tumorigenicity in vitro. Intratumoral delivery of synthetic miR-708 oligonucleotides triggered regression of established tumors in a murine xenograft model of human prostate cancer. Conversely, miR-708 silencing in a purified CD44- population of prostate cancer cells promoted tumor growth. Functional studies validated CD44 to be a direct target of miR-708 and also identified the serine/threonine kinase AKT2 as an additional target. Clinically, low miR-708 expression was associated significantly with poor survival outcome, tumor progression, and recurrence in patients with prostate cancer. Together, our findings suggest that reduced miR-708 expression leads to prostate cancer initiation, progression, and development by regulating the expression of CD44 as well as AKT2. miR-708 therefore may represent a novel therapeutic target or diagnostic and prognostic biomarker in prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
23. Up-Regulation of MicroRNA-21 Correlates with Lower Kidney Cancer Survival.
- Author
-
Zaman, Mohd Saif, Shahryari, Varahram, Guoren Deng, Thamminana, Sobha, Saini, Sharonjot, Majid, Shahana, Inik Chang, Hirata, Hiroshi, Koji Ueno, Yamamura, Soichiro, Singh, Kamaldeep, Tanaka, Yuichiro, Tabatabai, Z. Laura, and Dahiya, Rajvir
- Subjects
- *
MICRORNA , *RENAL cancer , *GENE expression , *CELL lines , *GENISTEIN , *APOPTOSIS , *CELL cycle - Abstract
Background: MicroRNA-21 is up-regulated in a variety of cancers like, breast, colorectal, lung, head and neck etc. However, the regulation of miR-21 in renal cell carcinoma (RCC) has not yet been studied systematically. Methods and Results: We measured miR-21 levels in 54 pairs of kidney cancers and their normal matched tissues by realtime PCR. The expression level of miR-21 was correlated with 5 year survival and the pathological stage. Functional studies were done after inhibiting miR-21 in RCC cell lines. We studied in vitro and in vivo effects of the chemo preventive agent genistein on miR-21 expression. In 48 cases (90%), miR-21 was increased. All patients with low miR-21 expression survived 5 years, while with high miR-21 expression, only 50% survived. Higher expression of miR-21 is associated with an increase in the stage of renal cancer. Functional studies after inhibiting miRNA-21 in RCC cell lines show cell cycle arrest, induction of apoptosis and reduced invasive and migratory capabilities. Western blot analysis showed an increase in the expression of p21 and p38 MAP kinase genes and a reduction in cyclin E2. Genistein inhibited the expression of miR-21 in A-498 cells and in the tumors formed after injecting genistein treated A-498 cells in nude mice besides inhibiting tumor formation. Conclusions: The current study shows a clear correlation between miR-21 expression and clinical characteristics of renal cancer. Thus we believe that miR-21 can be used as a tumor marker and its inhibition may prove to be useful in controlling cancers with up-regulated miR-21. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
24. Catechol-O-methyltransferase-mediated metabolism of 4-hydroxyestradiol inhibits the growth of human renal cancer cells through the apoptotic pathway.
- Author
-
Chang, Inik, Liu, Jan, Majid, Shahana, Saini, Sharanjot, Zaman, Mohd S., Yamamura, Soichiro, Shahryari, Varahram, Chiyomaru, Takeshi, Deng, Guoren, Dahiya, Rajvir, and Tanaka, Yuichiro
- Subjects
- *
CATECHOL-O-methyltransferase , *ESTRADIOL , *RENAL cancer diagnosis , *CANCER cells , *APOPTOSIS , *METABOLITES , *CARCINOGENESIS - Abstract
Long-term exposure to estrogen and its metabolites may play an important role in renal cell carcinogenesis. Catechol-O-methyltransferase (COMT) participates in the estrogen metabolism pathway by neutralizing toxic substances. Although reduced COMT activity has been suggested to be a risk factor for estrogen-associated cancers, no studies have investigated the biological significance of COMT in the pathogenesis of human renal cell cancers (RCCs). We initially found that COMT levels are significantly decreased in human RCC tissues and cells suggesting it plays a suppressive role in tumor development. However, transient overexpression of COMT has no functional effect on RCC cell lines. In contrast, when cells overexpressing COMT are treated with its substrate 4-hydroxyestradiol (4-OHE2), growth is inhibited by apoptotic cell death. We also found that COMT overexpression combined with 4-OHE2 induces upregulation of growth arrest- and DNA damage-inducible protein α (GADD45α). We further show that downregulation of GADD45α by a small interfering RNA-mediated approach inhibits cell death, indicating the essential role of GADD45α in the underlying mechanism of COMT action in response to 4-OHE2. Finally, 4-methoxyestradiol fully reproduces the antiproliferative function of COMT with 4-OHE2 by promoting GADD45α induction. Together, these findings show that COMT in the presence of 4-OHE2 prevents RCC cell proliferation by enhancing apoptosis and that GADD45α plays a critical role in the COMT-mediated inhibition of RCC. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
25. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer.
- Author
-
Suh, Seong O., Chen, Yi, Zaman, Mohd Saif, Hirata, Hiroshi, Yamamura, Soichiro, Shahryari, Varahram, Liu, Jan, Tabatabai, Z.Laura, Kakar, Sanjay, Deng, Guoren, Tanaka, Yuichiro, and Dahiya, Rajvir
- Subjects
- *
NON-coding RNA , *GENETIC regulation , *DNA , *METHYLATION , *P53 antioncogene , *GENETIC mutation , *PROSTATE cancer , *CELL lines , *GENE expression - Abstract
MiR-145 is downregulated in various cancers including prostate cancer. However, the underlying mechanisms of miR-145 downregulation are not fully understood. Here, we reported that miR-145 was silenced through DNA hypermethylation and p53 mutation status in laser capture microdissected (LCM) prostate cancer and matched adjacent normal tissues. In 22 of 27 (81%) prostate tissues, miR-145 was significantly downregulated in the cancer compared with the normal tissues. Further studies on miR-145 downregulation mechanism showed that miR-145 is methylated at the promoter region in both prostate cancer tissues and 50 different types of cancer cell lines. In seven cancer cell lines with miR-145 hypermethylation, 5-aza-2′-deoxycytidine treatment dramatically induced miR-145 expression. Interestingly, we also found a significant correlation between miR-145 expression and the status of p53 gene in both LCM prostate tissues and 47 cancer cell lines. In 29 cell lines with mutant p53, miR-145 levels were downregulated in 28 lines (97%), whereas in 18 cell lines with wild-type p53 (WT p53), miR-145 levels were downregulated in only 6 lines (33%, P < 0.001). Electrophoretic mobility shift assay showed that p53 binds to the p53 response element upstream of miR-145, but the binding was inhibited by hypermethylation. To further confirm that p53 binding to miR-145 could regulate miR-145 expression, we transfected WT p53 and MUT p53 into PC-3 cells and found that miR-145 is upregulated by WT p53 but not with MUTp53. The apoptotic cells are increased after WT p53 transfection. In summary, this is the first report documenting that downregulation of miR-145 is through DNA methylation and p53 mutation pathways in prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
26. MicroRNA-205-Directed Transcriptional Activation of Tumor Suppressor Genes in Prostate Cancer.
- Author
-
Majid, Shahana, Dar, Altaf A., Saini, Sharanjot, Yamamura, Soichiro, Hirata, Hiroshi, Tanaka, Yuichiro, Deng, Guoren, and Dahiya, Rajvir
- Subjects
- *
NON-coding RNA , *TUMOR suppressor genes , *INTERLEUKINS , *GENE expression , *PROSTATE cancer - Abstract
This article presents a study which demonstrated that microRNA-205, small noncoding RNA that regulate the expression of human genes, induced the expression of interleukin (IL) tumor suppressor genes by targeting specific sites in their promoters. Methods used in the investigation include transfection of small RNA, quantitative real-time polymerase chain reaction, and in situ hybridization. The results revealed that microRNA-205 was silenced in prostate cancer.
- Published
- 2010
- Full Text
- View/download PDF
27. Wnt Antagonist Gene Polymorphisms and Renal Cancer.
- Author
-
Hirata, Hiroshi, Hinoda, Yuji, Nakajima, Koichi, Kikuno, Nobuyuki, Yamamura, Soichiro, Kawakami, Kazumori, Suehiro, Yutaka, Tabatabai, Laura, lshii, Nobuhisa, and Dahiya, Rajvir
- Subjects
- *
GENETIC polymorphisms , *POPULATION genetics , *RENAL cell carcinoma , *CANCER patients , *CANCER risk factors , *RENAL cancer - Abstract
The article reports on the result of the study concerning polymorphisms in Wnt signaling genes as a possible risk for patients having renal cancer. The study includes 210 patients with renal cell carcinoma (RCC) and 200 age-matched and sex-matched control individuals. Result shows a significant decrease among patients with RCC in the frequency of the guanine/adenine (G/A) + A/A genotype in the DKK3 codon 335 rs3206824.
- Published
- 2009
- Full Text
- View/download PDF
28. MED1/TRAP220 Exists Predominantly in a TRAP/ Mediator Subpopulation Enriched in RNA Polymerase II and Is Required for ER-Mediated Transcription
- Author
-
Zhang, Xiaoting, Krutchinsky, Andrew, Fukuda, Aya, Chen, Wei, Yamamura, Soichiro, Chait, Brian T., and Roeder, Robert G.
- Subjects
- *
NUCLEIC acids , *RNA polymerases , *TRANSCRIPTION factors , *STEROID hormones - Abstract
Summary: Human TRAP/Mediator is a key coactivator for many transcription factors that act through direct interactions with distinct subunits, and MED1/TRAP220 is the main subunit target for various nuclear receptors. Remarkably, the current study shows that MED1/TRAP220 only exists in a TRAP/Mediator subpopulation (less then 20% of the total) that is greatly enriched in specific TRAP/Mediator subunits and is tightly associated with a near stoichiometeric level of RNA polymerase II. Importantly, this MED1/TRAP220-containing holoenzyme supports both basal- and activator-dependent transcription in an in vitro system lacking additional RNA polymerase II. Furthermore, chromatin immunoprecipitation experiments demonstrate an activator-selective recruitment of MED1/TRAP220-containing versus MED1/TRAP220-deficient TRAP/Mediator complexes to estrogen receptor (ER) and p53 target genes, respectively. Finally, RNAi studies show that MED1/TRAP220 is required for ER-mediated transcription and estrogen-dependent breast cancer cell growth. These observations have significant implications for our current understanding of the composition, heterogeneity, and functional specificity of TRAP/Mediator complexes. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
29. Structural and Functional Organization of TRAP220, the TRAP/Mediator Subunit That Is Targeted by Nuclear Receptors.
- Author
-
Malik, Sohail, Guermah, Mohamed, Chao-Xing Yuan, Wu, Weizhen, Yamamura, Soichiro, and Roeder, Robert G
- Subjects
- *
NUCLEAR receptors (Biochemistry) , *TRANSCRIPTION factors , *FIBROBLASTS , *BINDING sites , *BIOCHEMISTRY , *MOLECULAR biology - Abstract
The TRAP/Mediator complex serves as a coactivator for many transcriptional activators, including nuclear receptors such as the thyroid hormone receptor (TR) that targets the TRAP220 subunit. The critical but selective function of TRAP220 is evidenced by the embryonic lethal phenotype of Trap220-/- mice and by the observation that Trap220-/- fibroblasts (isolated before embryonic death) are impaired in specific nuclear receptor-dependent pathways. Here we have used a biochemical and genetic approach to understand the basis of specificity in TRAP220 function. We show that Trap220-/- cells possess a TRAP/Mediator complex that is relatively intact and compromised in its ability to support TR-dependent, but not VP16-dependent, transcription in vitro. Transfection studies using TRAP220 mutants revealed that the N terminus of TRAP220 is necessary and sufficient for stable association with the TRAP/Mediator complex and, further, that TRAP220- dependent TR function in transfected cells requires both of the NR boxes that contain the LXXLL motif implicated in nuclear receptor binding. Similarly, an analysis of isolated TRAP/Mediator complexes with mutations in either or both of the two NR boxes confirmed a critical role for them in in vitro coactivator function. The implications of these observations are discussed in terms of our present understanding of coactivator function. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
30. Role of the PI3K/Akt pathway in cadmium induced malignant transformation of normal prostate epithelial cells.
- Author
-
Kulkarni, Priyanka, Dasgupta, Pritha, Bhat, Nadeem S., Hashimoto, Yutaka, Saini, Sharanjot, Shahryari, Varahram, Yamamura, Soichiro, Shiina, Marisa, Tanaka, Yuichiro, Dahiya, Rajvir, and Majid, Shahana
- Subjects
- *
PROSTATE , *CADMIUM , *EPITHELIAL cells , *GENETIC regulation , *MITOGEN-activated protein kinases , *PROSTATE cancer - Abstract
This study investigated the role of the PI3K/Akt pathway in cadmium (Cd) induced malignant transformation of normal prostate epithelial (PWR1E and RWPE1) cells. Both PWR1E and RWPE1 cells were exposed to 10 μM Cd for one year and designated as Cd-PWR1E and Cd-RWPE1. Cd-RWPE1 cells robustly formed tumors in athymic nude mice. Functionally, Cd-exposure induced tumorigenic attributes indicated by increased wound healing, migration and invasion capabilities in both cell lines. RT2-array analysis revealed many oncogenes including P110α, Akt, mTOR, NFKB1 and RAF were induced whereas tumor suppressor (TS) genes were attenuated in Cd-RWPE1. This was validated by individual quantitative-real-time-PCR at transcriptional and by immunoblot at translational levels. These results were consistent in Cd-PWR1E vs parental PWR1E cells. Gene Set Enrichment Analysis revealed that five prostate cancer (PCa) related pathways were enriched in Cd-exposed cells compared to their normal controls. These pathways include the KEGG- Pathways in cancer, Prostate Cancer Pathway, ERBB, Apoptosis and MAPK pathways. We selected up- and down-regulated genes randomly from the PI3K/Akt pathway array and profiled these in the TCGA/GDC prostate-adenocarcinoma (PRAD) patient cohort. An upregulation of oncogenes and downregulation of TS genes was observed in PCa compared to their normal controls. Taken together, our study reveals that the PI3K/Akt signaling is one of the main molecular pathways involved in Cd-driven transformation of normal prostate epithelial cells to malignant form. Understanding the molecular mechanisms involved in the Cd-driven malignant transformation of normal prostate cells will provide a significant insight to develop better therapeutic strategies for Cd-induced prostate cancer. • Normal prostate epithelial RWPE1 and PWR1E cells were exposed to cadmium (Cd). • Cadmium exposed RWPE1 (Cd-RWPE1) cells formed tumors in nude mice. • Molecular mechanism involved the PI3K/Akt pathway genes. • Activation of these genes was observed at transcription and translation levels. • Gene Set Enrichment Analysis showed enrichment of prostate cancer related pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
31. Activation of the Erk/MAPK signaling pathway is a driver for cadmium induced prostate cancer.
- Author
-
Dasgupta, Pritha, Kulkarni, Priyanka, Bhat, Nadeem S., Majid, Shahana, Shiina, Marisa, Shahryari, Varahram, Yamamura, Soichiro, Tanaka, Yuichiro, Gupta, Ravi Kumar, Dahiya, Rajvir, and Hashimoto, Yutaka
- Subjects
- *
MITOGEN-activated protein kinases , *PROSTATE cancer , *CADMIUM , *APOPTOSIS inhibition , *GENETIC regulation , *CADMIUM poisoning - Abstract
Cadmium (Cd) is reported to be associated with carcinogenesis. The molecular mechanisms associated with Cd-induced prostate cancer (PCa) remain elusive. RWPE1, PWR1E and DU 145 cells were used. RT2 Profiler Array, real-time-quantitative-PCR, immunofluorescence, cell cycle, apoptosis, proliferation and colony formation assays along with Gene Set Enrichment Analysis (GSEA) were performed. Chronic Cd exposure of non-malignant RWPE1 and PWR1E cells promoted cell survival, proliferation and colony formation with inhibition of apoptosis. Even a two-week Cd exposure of PCa cell line (DU 145) significantly increased the proliferation and decreased apoptosis. RT2 profiler array of 84 genes involved in the Erk/MAPK pathway revealed induction of gene expression in Cd-RWPE1 cells compared to RWPE1. This was confirmed by individual TaqMan gene expression analysis in both Cd-RWPE1 and Cd-PWR1E cell lines. GSEA showed an enrichment of the Erk/MAPK pathway along with other pathways such as KEGG-ERBB, KEGG-Cell Cycle, KEGG-VEGF, KEGG-Pathways in cancer and KEGG-prostate cancer pathway. We randomly selected upregulated genes from Erk/MAPK pathway and performed profile analysis in a PCa data set from the TCGA/GDC data base. We observed upregulation of these genes in PCa compared to normal samples. An increase in phosphorylation of the Erk1/2 and Mek1/2 was observed in Cd-RWPE1 and Cd-PWR1E cells compared to parental cells, confirming that Cd-exposure induces activation of the Erk/MAPK pathway. This study demonstrates that Erk/MAPK signaling is a major pathway involved in Cd-induced malignant transformation of normal prostate cells. Understanding these dominant oncogenic pathways may help develop optimal therapeutic strategies for PCa. • Normal prostate epithelial RWPE1 and PWR1E cells were exposed to cadmium (Cd). • Chronic Cd exposure transformed these normal cells to malignant form. • Molecular mechanism involved was the Erk/MAPK signaling genes. • Activation of these genes was observed at transcription and translation levels. • Gene Set Enrichment Analysis showed enrichment of prostate cancer related pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Targeting the Epigenetic Non-Coding RNA MALAT1/Wnt Signaling Axis as a Therapeutic Approach to Suppress Stemness and Metastasis in Hepatocellular Carcinoma.
- Author
-
Chang, Hang-Lung, Bamodu, Oluwaseun Adebayo, Ong, Jiann-Ruey, Lee, Wei-Hwa, Yeh, Chi-Tai, Tsai, Jo-Ting, Yamamura, Soichiro, and Shiina, Marisa
- Subjects
- *
HEPATOCELLULAR carcinoma , *NON-coding RNA , *CATENINS , *LIVER cells , *CELL populations , *WNT signal transduction , *WNT genes , *CANCER stem cells - Abstract
Background: With recorded under-performance of current standard therapeutic strategies as highlighted by high rates of post-treatment (resection or local ablation) recurrence, resistance to chemotherapy, poor overall survival, and an increasing global incidence, hepatocellular carcinoma (HCC) constitutes a medical challenge. Accumulating evidence implicates the presence of HCC stem cells (HCC-SCs) in HCC development, drug-resistance, recurrence, and progression. Therefore, treatment strategies targeting both HCC-SCs and non-CSCs are essential. Methods: Recently, there has been an increasing suggestion of MALAT1 oncogenic activity in HCC; however, its role in HCC stemness remains unexplored. Herein, we investigated the probable role of MALAT1 in the SCs-like phenotype of HCC and explored likely molecular mechanisms by which MALAT1 modulates HCC-SCs-like and metastatic phenotypes. Results: We showed that relative to normal, cirrhotic, or dysplastic liver conditions, MALAT1 was aberrantly expressed in HCC, similar to its overexpression in Huh7, Mahlavu, and SK-Hep1 HCC cells lines, compared to the normal liver cell line THLE-2. We also demonstrated a positive correlation between MALAT1 expression and poor cell differentiation status in HCC using RNAscope. Interestingly, we demonstrated that shRNA-mediated silencing of MALAT1 concomitantly downregulated the expression levels of β-catenin, Stat3, c-Myc, CK19, vimentin, and Twist1 proteins, inhibited HCC oncogenicity, and significantly suppressed the HCC-SCs-related dye-effluxing potential of HCC cells and reduced their ALDH-1 activity, partially due to inhibited MALAT1-β-catenin interaction. Additionally, using TOP/FOP (TCL/LEF-Firefly luciferase) Flash, RT-PCR, and western blot assays, we showed that silencing MALAT1 downregulates β-catenin expression, dysregulates the canonical Wnt signaling pathway, and consequently attenuates HCC tumorsphere formation efficiency, with concurrent reduction in CD133+ and CD90+ HCC cell population, and inhibits tumor growth in SK-Hep1-bearing mice. Conclusions: Taken together, our data indicate that MALAT1/Wnt is a targetable molecular candidate, and the therapeutic targeting of MALAT1/Wnt may constitute a novel promising anticancer strategy for HCC treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.